IMGN901 in Combination With Lenalidomide and Dexamethasone

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

October 31, 2014

Conditions
Multiple Myeloma
Interventions
DRUG

IMGN901

dose escalation study. dosing on days 1, 8 and 15 every 28 days

Trial Locations (9)

10021

Weill Medical College, New York

14263

Roswell Park Cancer Institute, Buffalo

19111

Fox Chase Cancer Center, Philadelphia

27710

Duke University Medical Center, Durham

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

78229

CTRC at University of Texas Health Science Center, San Antonio

90033

University of Southern California, Los Angeles

92262

Comprehensive Cancer Center of the Desert, Palm Springs

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY

NCT00991562 - IMGN901 in Combination With Lenalidomide and Dexamethasone | Biotech Hunter | Biotech Hunter